Merck's most recent trend suggests a bearish bias. One trading opportunity on Merck is a Bear Call Spread using a strike $57.50 short call and a strike $62.50 long call offers a potential 13.38% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $57.50 by expiration. The full premium credit of $0.59 would be kept by the premium seller. The risk of $4.41 would be incurred if the stock rose above the $62.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Merck is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Merck is bearish.
The RSI indicator is at 22.62 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Merck
Bristol-Myers Squibb’s Oncology Portfolio in 4Q17
Mon, 12 Feb 2018 22:05:08 +0000
Must-Read Notes on Bristol-Myers Squibb’s 4Q17 and 2017 Earnings
Portland digital health pioneer acquired by Merck subsidiary
Mon, 12 Feb 2018 21:56:15 +0000
Provata Health, a fast-growing Portland-based digital health company serving 1,000 workplaces, has been acquired by a wholly owned subsidiary of Merck & Co Inc. Provata employees will join StayWell, giving the Yardley, Pa., company a presence in Portland, according to the companies’ announcement. Provata generated $2.7 million in 2015 revenue (the last year for which such data is available) and employed 25 workers in 2018.
What’s Pfizer’s Valuation after 4Q17 Earnings?
Mon, 12 Feb 2018 14:02:50 +0000
How Did Pfizer Fare in 4Q17?
What’s Expected of Novartis’s Net Profit Margin in 2018?
Mon, 12 Feb 2018 12:37:08 +0000
For 4Q17, Novartis (NVS) reported core operating income of around $3.2 billion, which represents a YoY (year-over-year) rise of 7% on a reported basis and a 5% YoY rise on a CC (constant currency) basis. For fiscal 2017, Novartis reported core operating income of ~$12.9 billion, which represents a YoY decline of 1% on a reported basis but a flat performance on a CC basis.
What Investors Should Know about Pfizer’s Recent Developments
Mon, 12 Feb 2018 12:33:17 +0000
How Did Pfizer Fare in 4Q17?
Related Posts
Also on Market Tamer…
Follow Us on Facebook